Research programme: antifibrotics - Nitto Denko/Quark Pharmaceuticals

Drug Profile

Research programme: antifibrotics - Nitto Denko/Quark Pharmaceuticals

Latest Information Update: 19 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nitto Denko; Quark Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Small interfering RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Fibrosis

Most Recent Events

  • 12 Jun 2013 Early research is ongoing Japan
  • 15 Jul 2010 Early research in Fibrosis in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top